Sarepta Therapeutics Inc. has appointed Douglas Ingram as president and CEO, taking the place of Dr. Edward Kaye.
Ingram was previously the president of Allergan Inc., and also served as the president and CEO of Chase Pharmaceuticals, bringing more than 20 years of experience to Sarepta.
“Sarepta has a mission that matters, a deep pipeline to support that mission, and employees and a board that are single mindedly focused on success through improving the lives of those with devastating rare diseases,” Ingram said.
Kaye also spoke on Ingram’s acquisition of the position, commenting on what he would bring to the company.
“I am confident Sarepta has selected in Doug Ingram the right leader to build on our success to date and to drive value for the Company as he has done for Allergan and Chase Pharmaceuticals,” Kaye said.
Sarepta is dedicated to working on treatments for rare neuromuscular diseases through developing RNA-targeted therapeutics.
